Pra health sciences, inc. (PRAH)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13
Cash flows from operating activities:
Net income

40,660

74,801

83,007

41,055

44,256

71,107

1,854

42,282

39,215

-16,195

48,606

29,658

25,224

14,025

31,449

38,670

-15,969

28,504

23,659

12,415

17,187

-22,820

1,175

-4,056

-10,041

-39,943

Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization expense

32,278

29,436

29,263

28,591

27,608

28,084

28,270

28,554

27,339

28,081

18,853

16,101

15,192

17,260

17,708

17,585

16,953

19,735

19,762

19,220

19,235

23,424

23,904

24,598

24,638

25,333

Amortization of debt issuance costs

421

450

462

454

448

492

546

539

534

628

516

482

482

919

1,171

1,148

1,195

1,161

1,536

1,637

1,649

1,359

1,485

1,459

1,434

1,608

Amortization of terminated interest rate swaps

1,565

1,578

1,672

1,657

1,631

1,668

1,868

1,836

1,774

1,753

1,753

1,650

1,528

1,627

1,312

1,123

899

-

-

-

-

-

-

-

-

-

Stock-based compensation expense

15,425

15,427

11,244

9,916

9,247

8,674

7,771

6,399

6,299

4,930

3,450

2,306

1,930

2,127

1,666

1,770

1,504

1,642

1,614

1,245

775

738

969

868

892

132

Gain (Loss) on Extinguishment of Debt

-

-

-

-

-

-

-

-

-

-

-

-

-

-16,693

0

0

-21,485

-

-

-

-

-23,652

0

0

-1,384

-7,211

Change in fair value of acquisition-related contingent consideration

574

0

0

0

0

1,670

42,552

1,894

-11,578

75,893

-999

35

40

-

-

-

-

-

-

-

-

-

-

-

-

-1,103

Non-cash transaction related stock-based compensation expense

-

-

-

-

-

-

-

-

-

-

-

-

-

12,745

0

2,594

26,827

-

-

-

-

-

-

-

-

-

Unrealized foreign currency gains, net

4,788

-1,306

8,203

-8,397

7,967

3,176

-2,262

1,325

1,068

-4,294

-13,486

-15,853

-6,067

15,119

529

12,739

-3,888

4,715

3,670

-3,296

11,375

10,506

7,524

-3,164

-2,644

-2,057

Equity in income of unconsolidated joint ventures

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-795

Deferred income tax benefit

-18,524

1,501

-2,946

-11,941

-10,521

-5,834

1,860

-182

15,821

-48,575

-26,050

2,324

-3,614

-2,393

1,620

4,124

-13,820

-1,006

182

-642

-1,753

-12,846

1,775

-9,383

-11,514

-21,980

Other reconciling items

-135

186

-333

-537

78

22

510

-226

-336

-573

882

-510

-562

646

80

446

-567

2,323

-1,365

1,137

-2,538

-301

149

-395

-431

69

Changes in operating assets and liabilities, net of acquired assets and assumed liabilities:
Prepaid expenses and other assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-2,858

Accounts payable and other liabilities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-46,209

Income taxes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

3,130

Advanced billings

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

28,294

Accounts receivable, unbilled services and advanced billings

7,600

-15,285

28,318

39,423

36,848

4,465

-8,683

-3,285

24,520

84,447

-69,382

57,606

63,659

-20,977

4,843

30,063

17,384

149,851

-1,090

-16,121

-49,429

-43,848

26,082

-16,088

66,635

-13,947

Other operating assets and liabilities

-436

-

15,715

1,824

-13,250

-

-15,047

30,861

-15,495

-

34,583

-15,488

-5,452

-

6,785

17,404

5,746

-

-3,432

4,896

24,579

-

-8,158

-3,934

-16,440

-

Payment of acquisition-related contingent consideration

-

-

-

-

-

0

0

0

35,029

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by operating activities

60,582

187,572

70,799

-45,830

41,026

131,215

111,386

52,573

34,618

102,580

101,891

26,733

-10,796

93,339

42,656

3,653

20,399

80,226

42,245

26,551

3,406

32,575

4,719

37,067

-40,327

-23,939

Purchase of fixed assets

21,460

13,084

20,345

20,970

19,895

15,794

13,576

12,698

13,812

22,031

17,308

14,007

7,972

7,486

8,111

9,408

8,138

6,779

8,969

9,456

7,610

8,331

7,116

6,092

5,784

4,910

Proceeds from the sale of fixed assets

26

0

0

26

0

-

-

-

-

1

6

25

24

-

-

-

-

-

-

-

-

-

-

-

-

-

(Cash paid) proceeds received for interest on interest rate swap, net

780

409

-220

-440

-416

-56

-433

-31

339

111

172

250

341

0

306

305

302

-

-

-

-

-

-

-

-

-

Proceeds from RPS Parent Holding Corp. working capital settlement

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

15,000

-

Distributions from unconsolidated joint ventures

0

0

0

0

418

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Acquisition of Care Innovations, Inc., net of cash acquired

159,078

-

-

-

0

-

-

-

-

-

-

-

-

-

121

0

4,147

-

-

-

-

-

-

-

-

-

Net cash used in investing activities

-181,292

-13,493

-20,125

-20,504

-19,061

-15,738

-12,935

-12,649

-14,151

-87,821

-540,711

-50,599

-8,289

-7,476

-8,538

-6,013

-12,587

12,448

-63,525

-12,999

-7,610

-7,544

-7,116

-6,028

9,216

-1,018,959

Cash flows from financing activities:
Proceeds from issuance of long-term debt

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,263,443

Proceeds from accounts receivable financing agreement

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

120,000

-

-

-

-

-

-

-

-

-

Borrowings on line of credit

100,000

193,800

0

40,000

0

-

-

-

-

-

-

-

-

0

0

0

110,000

-

-

-

-

40,000

20,000

25,000

20,000

50,000

Repayments of line of credit

55,000

105,000

0

40,000

0

-

-

-

-

-

-

-

-

0

0

0

110,000

-

-

-

-

-

-

-

-

40,000

Repayments of long-term debt

6,250

1,191,533

25,000

0

0

109,999

100,000

7,198

7,197

98,638

11,250

7,812

7,813

689,000

0

0

133,559

0

10,000

15,000

15,000

302,100

2,225

2,225

2,225

567,063

Proceeds from common stock issued, net of underwriters discount

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

470,400

Payment of common stock issuance costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

525

-

-

-

-

-

Proceeds from stock issued under employee stock purchase plan and stock option exercises

2,908

15,639

15,414

4,347

10,419

12,109

17,030

0

2,243

779

3,647

1,761

1,049

17

272

326

40

54

0

13

14

-

-

-

-

-

Payment of debt prepayment and debt extinguishment costs

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

17,824

-

-

-

-

-

-

-

-

-

Payment of debt discount

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

8,250

Payments for debt issuance costs

470

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

48,957

Payment of acquisition-related contingent consideration

-

-

-

-

-

0

0

0

79,663

0

0

400

0

-

-

-

-

-

-

-

-

-

-

-

-

-

Dividends paid

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

4,346

Principal repayments of fixed assets purchased under a financing agreement

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

186

Net cash provided by financing activities

41,188

-121,749

-9,586

30,209

10,419

-97,890

-93,487

-43,518

-84,617

-16,661

516,885

13,549

-6,764

-70,850

272

326

-31,343

-19,946

10,000

-16,987

-15,511

12,173

-3,712

-32,192

17,775

1,115,041

Effects of foreign exchange changes on cash, cash equivalents, and restricted cash

-5,908

2,150

-1,513

741

506

-713

-678

-3,475

1,878

514

1,235

222

1,584

-1,253

270

-124

482

-1,378

-1,430

580

-1,474

-3,689

-2,283

497

-517

12

Change in cash, cash equivalents, and restricted cash

-85,430

54,480

39,575

-35,384

32,890

16,874

4,286

-7,069

-62,272

-1,388

79,300

-10,095

-24,265

13,760

34,660

-2,158

-23,049

71,350

-12,710

-2,855

-21,189

33,515

-8,392

-656

-13,853

72,155